Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021142884 - USE OF ASPIRIN IN PREPARATION OF PLATELET-TARGETED DRUG DELIVERY SYSTEM

Publication Number WO/2021/142884
Publication Date 22.07.2021
International Application No. PCT/CN2020/076506
International Filing Date 25.02.2020
IPC
A61K 9/51 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
A61K 47/46 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 47/34 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/704 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
704attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 41/00 2020.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • 东南大学 SOUTHEAST UNIVERSITY [CN]/[CN]
Inventors
  • 陈宝安 CHEN, Baoan
  • 沈艳飞 SHEN, Yanfei
  • 栾建凤 LUAN, Jianfeng
  • 杜颖 DU, Ying
  • 戴璐 DAI, Lu
  • 王淑君 WANG, Shujun
  • 周芳 ZHOU, Fang
  • 章美琳 ZHANG, Meilin
Agents
  • 南京苏高专利商标事务所(普通合伙) NANJING SUGAO PATENT AND TRADEMARK FIRM ( ORDINARY PARTNERSHIP)
Priority Data
202010040681.X14.01.2020CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE OF ASPIRIN IN PREPARATION OF PLATELET-TARGETED DRUG DELIVERY SYSTEM
(FR) UTILISATION D'ASPIRINE DANS LA PRÉPARATION D'UN SYSTÈME D'ADMINISTRATION DE MÉDICAMENT CIBLANT LES PLAQUETTES
(ZH) 阿司匹林在血小板靶向载药系统制备中的用途
Abstract
(EN)
Disclosed is the use of aspirin in the preparation of a platelet-targeted drug delivery system. Aspirin is co-incubated with a platelet in vitro to inhibit the aggregation and deformation of the platelet, so that the platelet is used as a carrier to encapsulate PLGA nanoparticles, wherein the PLGA nanoparticles are loaded with anti-tumor drugs and photodynamic drugs. Aspirin is used to inhibit the aggregation of the platelet and prevent the deformation of the platelet in vitro, so that a higher proportion of intact platelets is maintained and a higher encapsulation rate of nanoparticles and anti-tumor drugs is further achieved. Thus, an effective anti-tumor effect is achieved and the use process is safe and efficient.
(FR)
L'invention concerne l'utilisation d'aspirine dans la préparation d'un système d'administration de médicament ciblant les plaquettes. L'aspirine est co-incubée avec une plaquette in vitro pour inhiber l'agrégation et la déformation de la plaquette, de telle sorte que la plaquette est utilisée en tant que support pour encapsuler des nanoparticules de PLGA, les nanoparticules de PLGA étant chargées avec des médicaments antitumoraux et des médicaments photodynamiques. L'aspirine est utilisée pour inhiber l'agrégation de la plaquette et empêcher la déformation de la plaquette in vitro, de sorte qu'une proportion plus élevée de plaquettes intactes soit maintenue et qu'un taux d'encapsulation plus élevé de nanoparticules et de médicaments antitumoraux soit également obtenu. Ainsi, un effet anti-tumoral efficace est obtenu et le processus d'utilisation est sûr et efficace.
(ZH)
阿司匹林在血小板靶向载药系统制备中的用途,将阿司匹林与血小板体外共孵育,抑制血小板聚集变形,从而使血小板作为载体包封PLGA纳米粒子,PLGA纳米粒子装载抗肿瘤药物及光动力药物。利用阿司匹林体外抑制血小板聚集,预防血小板变形,保持较高比例的完整血小板,从而进一步实现较高的纳米粒子及抗肿瘤药物的包封率,以此实现有效的抗肿瘤作用,使用过程中安全、高效。
Latest bibliographic data on file with the International Bureau